Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937859 | 0.92 | KEAP1 (0.50) | KEAP1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL5951820 | 0.84 | DGAT1 (0.40) | KEAP1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL15042789 | 0.84 | KDM4E (0.46) | KEAP1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL3436916 | 0.83 | KDM4E (0.45) | KEAP1KDM4EGABRPGABRDGABRA1 | |
| SCHEMBL30079667 | 0.83 | KDM4E (0.52) | KEAP1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL222733 | 0.83 | KEAP1 (0.57) | KEAP1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL974647 | 0.83 | KDM4E (0.52) | KEAP1KDM4EKMT2ATDP1MEN1 | |
| SCHEMBL12931050 | 0.81 | KDM4E (0.44) | KEAP1KDM4EGABRPGABRDGABRA1 | |
| SCHEMBL2892593 | 0.81 | GABRP (0.52) | KEAP1KDM4EKMT2ATDP1MEN1 | |
| Hydrochloric Acid SCHEMBL9388380 | 0.81 | KMT2A (0.52) | KEAP1KDM4EKMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4552654-A1 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-11919905-B2 | Substituted benzo[f]imidazo[1,2-a][1,4]diazepines as anesthetics | Hangzhou Adamerck Pharmlabs, Inc. (CN) | 2024-03-05 | — | — | US | disclosed |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3730495-B1 | PYRIDYL IMIDAZOBENZODIAZEPINE PROPIONATE COMPOUND AND SYNTHESIS AND USE THEREOF | HANGZHOU ADAMERCK PHARMLABS INC (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-111727190-B | Pyridylimidazole benzodiazepine Zhuo Bingsuan ester compound and synthesis and application thereof | 杭州奥默医药股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023103850-A1 | SMALL MOLECULE STING AGONIST, PREPARATION METHOD THEREFOR, AND APPLICATION | 中国科学院上海药物研究所 | 2023-06-15 | — | — | WO | disclosed |
| EP-3730495-A1 | PYRIDYL IMIDAZOBENZODIAZEPINE PROPIONATE COMPOUND AND SYNTHESIS AND USE THEREOF | Hangzhou Adamerck Pharmlabs Inc. (CN) | 2020-10-28 | — | — | EP | disclosed |
| CN-111727190-A | Pyridyl imidazobenzodiazepine propionate compound and synthesis and application thereof | 杭州奥默医药股份有限公司 | 2020-09-29 | — | — | CN | disclosed |
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| EP-2098512-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly & Company (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| CN-1863778-A | Compounds and methods for treating dyslipidemia | LILLY CO ELI (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919905-B2 | Substituted benzo[f]imidazo[1,2-a][1,4]diazepines as anesthetics | GABRA1, GABRA4, GABRA6 | KEAP1 4266/4885KDM4E 378/4885KMT2A 440/4885 |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | APOB, CETP, PCSK9 | KEAP1 1682/4885KDM4E 3781/4885KMT2A 3153/4885 |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | FCGR1A, FCGRT, FCGR2A | KEAP1 2616/4885KDM4E 3722/4885KMT2A 1569/4885 |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | KEAP1 148/4885KDM4E 3849/4885KMT2A 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.